Bioventus Inc.

Bioventus Inc.(BVS)股票分析

$14.960

-0.079 (-0.53%)收盤時

Loading chart…
最高
15.090
開盤
14.940
成交量加權均價
14.94
成交量
387.05K
市值
365.09M
最低
14.762
成交金額
5.78M
企業價值/稅息折舊攤銷前利潤(TTM)
9.72

Bioventus Inc. is a medical device company. The Company’s portfolio of products is grouped into three areas. Its Pain Treatments include the Knee Osteoarthritis (KOA) area, and Peripheral Nerve Stimulation (PNS) area. Its Surgical Solutions include Ultrasonics, which offers precision bone resection for patients with degenerative spine conditions and spinal deformities, and Bone Graft Substitutes (BGS), which includes a range of products that facilitate optimal bone fusion following a surgical procedure. Its Restorative Therapies comprise Fracture Care that provide low-intensity pulse ultrasound to help patients who suffer from bone fractures that do not heal through traditional methods. It offers a diverse portfolio of products to support physicians in relieving pain and addressing musculoskeletal challenges across indications and clinical areas, including knee, hand and upper extremities, foot and ankle, podiatry, trauma, general surgery, spine and neurosurgery.

AI 分析 of Bioventus Inc. (BVS)

買進

Bioventus Inc is a good buy right now, given its current price of $13.30 and a forward P/E of 14.79, which suggests the stock is reasonably valued compared to its earnings potential. Additionally, the company has shown a significant year-to-date change of +84.47%, indicating strong momentum. The main risk is the recent strategic review initiated by the Board, which could lead to uncertainty regarding the company's future direction.

估值指標

Bioventus Inc.(BVS)目前預期本益比為 14.79,5 年平均預期本益比為 21.51。

預期本益比

合理
5 年均值 P/E
21.51
目前P/E
14.79
高估
53.11
低估
-10.09

預期 EV/EBITDA

合理
5 年均值 EV/EBITDA
8.82
目前EV/EBITDA
9.72
高估
10.92
低估
6.72

預期股價營收比

高估
5 年均值 P/S
0.87
目前P/S
1.51
高估
1.28
低估
0.46

Alphio AI 對 BVS 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%BVS

$7.26

情境價格

基

基準

基準 · 50%BVS

$5.98

情境價格

悲

悲觀

悲觀 · 25%BVS

$5.88

情境價格

持有 BVS 的大戶

P

Pinnacle Investment Management Group Limited

+ 持有BVS

-14.16%

3個月報酬率

事件時間軸

2026-08-05 (ET)

08:30:00

Bioventus Initiates Review of Strategic Alternatives

2026-06-30 (ET)

14:00:00

AWS Invests $1 Billion to Establish Forward Deployed Engineering Organization

2026-05-06 (ET)

08:10:00

Bioventus Raises FY26 Revenue Guidance to $600M

08:10:00

Bioventus Q1 Revenue $132.09M, Exceeds Expectations

2026-03-05 (ET)

07:20:00

Bioventus Reports Q4 Revenue of $157.9M, Beating Expectations

資訊

BVS 常見問題 —— 由 Alphio AI 解答

Bioventus Inc. is a medical device company. The Company’s portfolio of products is grouped into three areas. Its Pain Treatments include the Knee Osteoarthritis (KOA) area, and Peripheral Nerve Stimulation (PNS) area. Its Surgical Solutions include Ultrasonics, which offers precision bone resection for patients with degenerative spine conditions and spinal deformities, and Bone Graft Substitutes (BGS), which includes a range of products that facilitate optimal bone fusion following a surgical procedure. Its Restorative Therapies comprise Fracture Care that provide low-intensity pulse ultrasound to help patients who suffer from bone fractures that do not heal through traditional methods. It offers a diverse portfolio of products to support physicians in relieving pain and addressing musculoskeletal challenges across indications and clinical areas, including knee, hand and upper extremities, foot and ankle, podiatry, trauma, general surgery, spine and neurosurgery. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Bioventus Inc is a good buy right now, given its current price of $13.30 and a forward P/E of 14.79, which suggests the stock is reasonably valued compared to its earnings potential. Additionally, the company has shown a significant year-to-date change of +84.47%, indicating strong momentum. The main risk is the recent strategic review initiated by the Board, which could lead to uncertainty regarding the company's future direction.

暫無貼文

註冊或登入後參與討論

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易